ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0586

Transcription Factor Fli-1 Impacts CXCL13 Expression and Renal Inflammation in Lupus-like Nephritis of Adult MRL/lpr Mouse

Shuzo Sato1, Xian Zhang2, Naoki Matsuoka1, Yuya Sumichika1, Kenji Saito1, Shuhei Yoshida1, Haruki Matsumoto1, Jumpei Temmoku1, Yuya Fujita1, Tomoyuki Asano1, Hiroshi Watanabe1 and Kiyoshi Migita1, 1Fukushima Medical University, Fukushima, Japan, 2Medical University of South Carolina, Charleston, SC

Meeting: ACR Convergence 2022

Keywords: Animal Model, chemokines, Lupus nephritis, Systemic lupus erythematosus (SLE), transcription factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Cytokines and Cell Trafficking Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Friend leukemia virus integration 1 (Fli-1) belongs to the Ets family of transcription factors and plays an important role in the development of lupus nephritis. Previously, we have reported that Fli-1 regulates cytokine/chemokine expression (MCP-1, RANTES, IL-6, G-CSF, CXCL2, IL-17A, GM-CSF and CXCL10) and impacts immune cell infiltration into the kidney in lupus model mouse. CXCL13 is an important chemokine which promotes formation of ectopic lymphoid structures and has been reported to be associated with the pathogenesis of lupus nephritis. So far, the relationship between Fli-1 and CXCL13 is unknown. This study aims to elucidate whether Fli-1 impacts CXCL13 expression and contribute to the progression of lupus-like nephritis in adult MRL/lpr mouse.

Methods: Serum CXCL13 levels were measured in adult wild-type (WT, Fli-1+/+) MRL/lpr mice and Fli-1 heterozygote knockout (Fli-1+/-, homozygous knockout of Fli-1 results lethal in uetro) MRL/lpr mice (4-month-old or older) by ELISA. Renal mRNA expression (CXCL13, CXCR5, etc.) were measured using real-time PCR method. Kidneys were removed, stained and evaluated using pathology scoring system as previously described (Zhang et al. J Immunol 2004). Next, immunostaining using anti-CXCL13 or anti-CXCR5 antibodies were preformed and evaluated to compare the grade of CXCL13/CXCR5 positive immune cells infiltration (total number of positive cells in ten random high-power fields, Sato et al. Cells 2020). We also performed immunofluorescence staining by specific antibodies of CXCL13 and CD11b to detect infiltration of CXCL13/CD11b double positive immune cells.

Results: Serum CXCL13 levels were significantly lower in Fli-1+/- MRL/lpr mice than WT MRL/lpr mice (575 and 977 pg/mL, p=0.02) (Figure 1A). Serum IL-6 levels were also decreased in Fli-1+/- MRL/lpr mice. Renal expression of CXCL13 mRNA and Sox4 (an important transcription factor for B cell development) levels were significantly decreased in Fli-1+/- MRL/lpr mice (Figure 1C). Renal histology showed increased glomerular inflammation in WT MRL/lpr mice (Figure 2A,B,G). In contrast, the grade of interstitial inflammation was similar between the 2 groups (Figure 2G). In immunohistochemistry, the number of both CXCL13 and CXCR5 positive cells were significantly deceased in Fli-1+/- MRL/lpr mice compared to WT mice, despite similar interstitial immune cell infiltration into the kidney (Figure 2C,D,G,H). Furthermore, immunofluorescence staining showed significantly decreased CXCL13/CD11b double positive cells in Fli-1+/- MRL/lpr mice (n=5-7, p< 0.01) (Figure 2E,F,I).

Conclusion: Fli-1 impacts CXCL13 expression and affects lupus-like nephritis through regulating renal Sox4 mRNA expression, infiltration of CXCR5 positive cells as well as CXCL13/CD11b double positive immune cells into the kidney.

Supporting image 1

Figure 1. A, B: Serum CXCL13 and IL-6 levels between WT and Fli_1+/- MRL/lpr mice. C: Relative mRNA expression of CXCL13, CXCR5, Bcl-6 and Sox4 between the 2 groups.

Supporting image 2

Figure 2. Histopathological evaluation in the kidney between WT and Fli_1+/- MRL/lpr mice. A and B, hematoxylin & eosin staining; C and D, immunostaining using anti-CXCL13 antibodies; E and F, immunofluorescence staining by anti-CXCL13 and anti-CD11b antibodies; G, histological scores in the glomerulus (Glom) and interstitial lesions (Int); H, total counts of CXCL13 or CXCR5-positive immune cells in random 10 high- power fields (HPF) into the kidney; I, total counts of CXCL13/CD11b double positive immune cells in 10 HPF.


Disclosures: S. Sato, None; X. Zhang, None; N. Matsuoka, None; Y. Sumichika, None; K. Saito, None; S. Yoshida, None; H. Matsumoto, None; J. Temmoku, None; Y. Fujita, None; T. Asano, None; H. Watanabe, None; K. Migita, Chugai, Pfizer, AbbVie/Abbott, Eli Lilly.

To cite this abstract in AMA style:

Sato S, Zhang X, Matsuoka N, Sumichika Y, Saito K, Yoshida S, Matsumoto H, Temmoku J, Fujita Y, Asano T, Watanabe H, Migita K. Transcription Factor Fli-1 Impacts CXCL13 Expression and Renal Inflammation in Lupus-like Nephritis of Adult MRL/lpr Mouse [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/transcription-factor-fli-1-impacts-cxcl13-expression-and-renal-inflammation-in-lupus-like-nephritis-of-adult-mrl-lpr-mouse/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transcription-factor-fli-1-impacts-cxcl13-expression-and-renal-inflammation-in-lupus-like-nephritis-of-adult-mrl-lpr-mouse/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology